

NOTE: ▼ Limited trial; not open ETCTN-wide

ETCTN Solid Tumors with Specific Mutations Trials (Open as of 11/10/2025)

Protocol Number	Phase	Protocol Title
10355	I	A Phase I Study of DS-8201a in Combination with Olaparib in HER2-Expressing Malignancies
10371	II	A Pharmacodynamics-Driven Trial of Talazoparib, an Oral PARP Inhibitor, in Patients with Advanced Solid Tumors and Aberrations in Genes Involved in DNA Damage Response
10528	I	Phase 1 study of the POLq inhibitor Novobiocin in BRCA-mutant and other DNA damage repair-deficient solid tumors
10527	lb	A Molecularly Driven Phase 1b Dose Escalation and Dose Expansion Study of the DNA-PK Inhibitor Peposertib (M3814) in Combination with the ATR Inhibitor M1774
10572	I	A Phase 1 Trial Evaluating the Combination of Temozolomide and the Ataxia Telangiectasia and Rad3-Related Inhibitor M1774
10495	I	Phase I Trial of DS-8201a (Trastuzumab Deruxtecan) in Combination with Neratinib in Solid Tumors with HER2 Alterations
10358	I/Ib	Phase 1/1B Study of DS-8201a in Combination with ATR Inhibition (AZD6738) in Advanced Solid Tumors with HER2 Expression (DASH Trial)
10720	lb	Phase 1b study of Pidnarulex and Trastuzumab Deruxtecan in patients with HER2 expressing Solid Tumors